img

Oral Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Formulation (Tablets, Capsules, Drops, Liquid or Syrup), By Type (Controlled Release, Orodispersible Tablets, Others), By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others), By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic


Published on: 2024-11-15 | No of Pages : 320 | Industry : Healthcare

Publisher : MIR | Format : PDF&Excel

Oral Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Formulation (Tablets, Capsules, Drops, Liquid or Syrup), By Type (Controlled Release, Orodispersible Tablets, Others), By Therapy Area (Oncology, Musculoskeletal, Immunology, Gastrointestinal, Respiratory, Cardiovascular, Others), By End User (Hospitals, Ambulatory Surgical Centres, Diagnostic

Forecast Period2025-2029
Market Size (2023)USD 120.44 Billion
Market Size (2029)USD 187.56 Billion
CAGR (2024-2029)7.74%
Fastest Growing SegmentTablets
Largest MarketNorth America

MIR Consumer Healthcare

Market Overview

Global Oral Drug Delivery Market was valued at USD 120.44 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.74% through 2029.The Oral Drug Delivery Market encompasses the sector within the pharmaceutical industry dedicated to the development, manufacturing, and commercialization of medications administered via the oral route. This market segment is of paramount importance as oral drug delivery is one of the most common and preferred methods for medication administration due to its convenience, ease of use, and patient compliance. Oral drug delivery systems encompass a wide range of formulations, including tablets, capsules, liquids, and orally disintegrating tablets, among others. Within this market, pharmaceutical companies invest heavily in research and development to innovate new drug delivery technologies aimed at enhancing drug efficacy, bioavailability, and patient outcomes.

Key Market Drivers

Rising Prevalence of Chronic Diseases

The escalating prevalence of chronic diseases worldwide, comprising ailments such as cardiovascular diseases, diabetes, and cancer, stands as a formidable driver propelling the growth trajectory of the Global Oral Drug Delivery Market. This surge in chronic conditions poses a significant healthcare challenge, necessitating effective management and treatment strategies. As the burden of chronic diseases continues to mount, there emerges an ever-growing demand for oral medications that provide not only therapeutic efficacy but also convenience and long-term management options for patients. Oral drug delivery systems offer a crucial solution by providing a non-invasive and easily administrable route for medication intake. This convenience factor plays a pivotal role in enhancing patient adherence to prescribed treatment regimens, a critical aspect in achieving optimal therapeutic outcomes. By simplifying the medication process and minimizing discomfort associated with other routes of drug administration, oral drug delivery systems effectively empower patients to adhere to their treatment plans diligently. Consequently, this enhanced patient compliance not only fosters better disease management but also drives the sustained growth and expansion of the Global Oral Drug Delivery Market, as pharmaceutical companies continue to invest in innovative formulations and technologies to meet the evolving needs of patients worldwide.

Technological Innovations in Drug Delivery Platforms

Technological innovations in drug delivery platforms are playing a pivotal role in shaping the evolution of the Global Oral Drug Delivery Market. With relentless advancements, novel delivery systems such as oral films, implants, and buccal patches have emerged as frontrunners, offering a paradigm shift in drug administration strategies. These cutting-edge technologies not only facilitate traditional drug delivery but also offer distinctive advantages such as targeted delivery, controlled release, and site-specific action, thus revolutionizing the treatment landscape.


MIR Segment1

Expanding Pharmaceutical Industry Investments

The Global Oral Drug Delivery Market derives substantial benefits from the considerable investments poured into research, development, and commercialization of oral drug delivery technologies by pharmaceutical companies. These investments serve as catalysts propelling innovation within the market, fostering the rapid introduction of novel oral formulations, and nurturing collaborative endeavors among industry stakeholders, thus fueling overall market growth.

Government Initiatives to Improve Healthcare Access

Government initiatives aimed at enhancing healthcare access and affordability play a pivotal role in bolstering the growth of the global oral drug delivery market. These initiatives encompass a spectrum of policies and programs geared towards fostering an environment conducive to market expansion, driving demand for oral medications, and promoting improved patient outcomes.

One significant aspect of government initiatives is the promotion of generic drug utilization through policies aimed at increasing affordability and accessibility of medications. By encouraging the use of generic equivalents of branded drugs, governments can lower healthcare costs for patients and healthcare systems alike, thereby expanding access to oral medications. This increased accessibility fosters market growth by broadening the patient base and driving demand for oral drug delivery products.

Government interventions in drug pricing regulations contribute to the growth of the Global Oral Drug Delivery Market. Price regulations aimed at controlling the cost of pharmaceuticals help ensure affordability for patients and healthcare systems, thereby stimulating demand for oral medications. By implementing policies that balance affordability with pharmaceutical innovation, governments create a stable market environment conducive to sustained growth and expansion.

Key Market Challenges

Bioavailability Enhancement

One of the foremost challenges facing the Global Oral Drug Delivery Market is enhancing the bioavailability of orally administered medications. Many drugs encounter significant degradation and poor absorption in the gastrointestinal tract, leading to reduced efficacy and therapeutic outcomes. Overcoming these barriers requires innovative formulation approaches, such as the use of nanotechnology, lipid-based formulations, and novel excipients, to improve drug solubility, permeability, and stability. Additionally, optimizing drug release profiles and absorption kinetics through controlled-release formulations and drug delivery systems represents a critical area of focus for pharmaceutical companies seeking to maximize the therapeutic potential of oral medications.


MIR Regional

Regulatory Compliance and Intellectual Property Protection

Regulatory compliance and intellectual property protection present significant challenges for companies operating in the Global Oral Drug Delivery Market. Developing innovative oral drug delivery technologies necessitates navigating complex regulatory frameworks to ensure compliance with safety, efficacy, and quality standards set forth by regulatory authorities worldwide. Additionally, protecting intellectual property rights is essential for safeguarding investments in research and development and maintaining a competitive edge in the market. Effective strategies for navigating regulatory requirements and securing intellectual property rights are essential for sustaining innovation and driving growth in the Global Oral Drug Delivery Market.

Key Market Trends

Personalized Medicine and Customized Formulations

One notable trend shaping the Global Oral Drug Delivery Market is the shift towards personalized medicine and customized formulations. As advancements in biotechnology and pharmacogenomics continue to unfold, there is an increasing recognition of the importance of tailoring drug therapies to individual patient characteristics such as genetic makeup, disease profile, and lifestyle factors. This trend is driving the development of innovative oral drug delivery systems capable of delivering precise dosages and formulations tailored to meet the unique needs of each patient. Pharmaceutical companies are investing in technologies such as 3D printing and nanotechnology to enable the production of personalized oral drug formulations, thereby enhancing treatment efficacy and patient outcomes.

Integration of Digital Health Technologies

Another significant trend in the Global Oral Drug Delivery Market is the integration of digital health technologies into oral drug delivery systems. With the proliferation of smartphones, wearables, and connected devices, there is a growing opportunity to enhance medication adherence, monitoring, and patient engagement through digital solutions. Pharmaceutical companies are increasingly incorporating features such as smart pill bottles, medication reminder apps, and real-time tracking sensors into oral drug delivery devices to empower patients and healthcare providers with actionable insights into medication adherence and treatment response. This trend not only improves patient outcomes but also facilitates data-driven decision-making and clinical research in the field of oral drug delivery.

Segmental Insights

Formulation Insights

Based on the Formulation, in the global Oral Drug Delivery Market, tablets stand out as the dominant formulation method. Tablets have secured their prominence due to several compelling factors. Tablets offer unparalleled convenience and ease of administration, making them a preferred choice for patients across diverse demographics. Their solid form allows for convenient storage, transport, and dosing accuracy, enhancing patient compliance and medication adherence.

Additionally, tablets facilitate precise dosing and formulation control, enabling pharmaceutical companies to deliver a wide range of active pharmaceutical ingredients (APIs) in a stable and reproducible manner. Furthermore, tablets can be manufactured using a variety of technologies, including immediate-release, modified-release, and extended-release formulations, catering to diverse therapeutic needs and patient preferences. Moreover, tablets often undergo rigorous quality control measures and stability testing, ensuring their efficacy, safety, and shelf-life. Overall, tablets' versatility, convenience, and reliability position them as the dominant formulation method in the global Oral Drug Delivery Market, driving their widespread adoption and market dominance.

Type Insights

Based on the Type segment, the Controlled Release type stands out as the dominant type among the various categories. This dominance can be attributed to several key factors. Controlled release formulations offer significant advantages over conventional immediate-release formulations by providing sustained and controlled drug release over an extended period. This allows for less frequent dosing, improved patient compliance, and enhanced therapeutic efficacy.

As a result, pharmaceutical companies are increasingly investing in the development of controlled release oral drug delivery systems across a wide range of therapeutic areas, including chronic diseases such as diabetes, hypertension, and pain management. Moreover, advancements in drug delivery technologies, such as matrix systems, osmotic pumps, and microencapsulation techniques, have enabled the precise modulation of drug release kinetics, further enhancing the therapeutic benefits of controlled release formulations.

Additionally, the growing prevalence of chronic diseases worldwide, coupled with an aging population and increasing healthcare expenditure, drives the demand for long-acting oral medications that offer sustained symptom relief and improved disease management. Consequently, the controlled release segment continues to dominate the global Oral Drug Delivery Market, offering significant growth opportunities for pharmaceutical companies and driving advancements in drug delivery science and technology.

Regional Insights

North America emerges as the dominant region in the Global Oral Drug Delivery Market. Several factors contribute to its prominence in this market segment. North America boasts a robust pharmaceutical industry with a high level of research and development investment, leading to continuous innovation in oral drug delivery technologies. The region benefits from advanced healthcare infrastructure and a well-established regulatory framework that facilitates the development, approval, and commercialization of oral drug delivery products.

A significant portion of pharmaceutical companies specializing in oral drug delivery systems are headquartered in North America, further bolstering its leadership position. Moreover, the region has a large patient population with a high prevalence of chronic diseases, driving the demand for oral medications and propelling market growth. Favorable reimbursement policies and strong market competition contribute to the dynamic and thriving nature of the oral drug delivery market in North America.

Recent Developments

  • In January 2024, LyndraTherapeutics, a biopharmaceutical company in the clinical stage, announced itslatest findings from the STARLYNG-1 (LYN-005-C-301) study. This study evaluatesthe pharmacokinetic (PK) characteristics of oral weekly risperidone (LYN-005)in comparison to the daily administration of immediate-release Risperdal inadults managing schizophrenia and schizoaffective disorder. Designed tovalidate the safety and effectiveness previously established forimmediate-release Risperdal in schizophrenia and bipolar disorder, theSTARLYNG-1 study aligns with the regulatory requirements set forth by the U.S.Food and Drug Administration.
  • In September 2023, HermesPharma, a Contract Development and Manufacturing Organization (CDMO) based inGermany, declared its intention to invest $26 million to upgrade itsmanufacturing capabilities for oral medications. The allocated funds will beutilized for acquiring new equipment, enhancing operational efficiency,expanding production capacity, and augmenting storage facilities. Thisinvestment aims to propel the future growth of Hermes Pharma, renowned for itsproduction of user-friendly oral dosage forms like orally disintegratinggranules and chewable tablets.

Key Market Players

  • Novartis AG
  • Biocon Ltd.
  • NovoNordisk A/S
  • F.Hoffmann-La Roche Ltd.
  • Bayer AG
  • Emishphere Technologies Inc.
  • Enteris Biopharma Inc.
  • Merrion Pharmaceuticals Plc.
  • Amgen Inc.
  • Pfizer Inc.

By Formulation

By Type

By Therapy Area

By End User

By Region

  • Tablets
  • Capsules
  • Drops
  • Liquid or Syrup
  • Controlled Release
  • Orodispersible Tablets
  • Others
  • Oncology
  • Musculoskeletal
  • Immunology
  • Gastrointestinal
  • Respiratory
  • Cardiovascular
  • Others
  • Hospitals
  • Ambulatory Surgical Centres
  • Diagnostic Centres
  • Clinics
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )
To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )